re: Ann: CAVATAK anti-cancer activity - US Ca...
Onaroll I appreciate your input.
You're post somewhat leads me to think that Biotech stocks don't appreciate in value until one day, suddenly, they turn a profit and all of a sudden give multiples of their preexisting value.
If you've been investing for so many years, I am sure you would be the first to admit that this is not the case.
There are numerous examples of companies which appreciate in value well before production or profit or revenue.
I agree with you entirely that VLA would be even better if it was generating a profit. However please don't for one minute insinuate that it would be sitting at the current share price give or take 50% as you put it.
Take a look at NEU. Market cap over $150mill. Phase two drug. Any profit? Any revenue?
This company has an EV of approx $30mill and has the potential to sell a treatment agent for a vast array of cancers. Now that is big big money.
No wonder the US instos jumped at the chance of getting on board.
VLA Price at posting:
35.5¢ Sentiment: Buy Disclosure: Held
